TMCnet News
Research and Markets: Inhaled Drug Delivery Seminar: London, UK - 5-6th November 2014DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/btpdfh/inhaled_drug) has announced the addition of the "Inhaled Drug Delivery (London, UK)" conference to their offering. Conference Date: 05-06 Nov 2014 Venue: The Rembrandt Hotel, London BENEFITS IN ATTENDING: - Hear the latest on market trends and opportunities - Gain an update on new technologies and developments - Understand new therapeutic fields for inhalation drug delivery - Keep abreast of new regulatory updates - Technology showcase for many companies - Excellent networking opportunity Key Topics Covered: Day One 09.30 - Chairman's Welcome and Introduction Dr Steve Nichols, OINDP Specialist Consultant, UK KEY NOTE ADDRESS 09.40 - COPD: New Drug Developments Professor Peter Barnes, Professor of Thoracic Medicine and Head of Respiratory Medicine, National Heart and Lung Institute, UK 10.20 - Is it the End of the Road for MDIs? Dr Tim Noakes, Mexichem Fluor, UK 11.00 - Discussion followed by Coffee 11.30 - Can we Improve the Way we Perform Clinical Trials? Dr John Pritchard, Chief Technology Officer for Respiratory Drug Delivery, Philips (News - Alert) Healthcare 12.10 - ASAP: Method of Determining Stability in Products - Using Science o Set Shelf Life Piero De Filippis, Stability Team Manager, Aptuit, Italy (invited) 12.50 - Discussion followed by Lunch PRODUCT APPROVALS 14.00 - Parallel Multiple Drug and Device Development - A Challenge too Far? Andrew Grant, Andrew Grant Associates, UK (invited) 14.40 - Afrezza® Inhaled Insulin - The Development of a Dry Powder Orally Inhaled Insulin Product Dr Andrea Leone-Bay, Vice President Pharmaceutical Research, MannKind Corp, USA 15.20 - Discussion followed by Tea FORMULATION 16.00 - Understanding Formulation Device Interactions - How Much can we Measure and Predict? Frank Thielmann, Operational Lead Inhalation New Solids, Novartis Pharma AG, Switzerland NOVEL INHALATION THERAPY - BIOLOGICALS 16.40 - Development of Inhaled Interferon Beta for the Prevention or Attenuation of Virus Induced Asthma Exacerbations Phillip Monk, Chief Scientific Officer, Synairgen Research Ltd, UK 17.20 - Discussion 17.30 - End of Day One 17.30 - Networking Drinks Reception for Delegates and Speakers Day Two 09.15 - Chairman's Review of Day One Dr Ian Smith, Director H12 Consulting, UK EMERGING MARKETS 9.30 - The Marketing Analytics of Inhalation Products for Asthma COPD in China Dr Anny Shen, Managing Director Bering Scientific Information Ltd. and Chairman of the Inhalation Drug Delivery Association, China NON-CLINICAL TESTING 10.10 - Twenty Critical Questions you Must ask When Planning to Dose by the Inhaled Route Dr Simon Moore, Head of Aerosol Technology, Huntingdon Life Sciences, UK 10.50 - Discussion 11.00 - Coffee FORMULATION 11.30 - Inhalation Strategies to Treat Respiratory Infections Dr. Hui Xin Ong, Respiratory Technology, Woolcock Institute, Sydney, Australia and Faculty of Heath Sciences, Southampton University 12.10 - Dissolution - A Critical Performance Characteristic of Inhaled Products Dr. Ben Forbes, Head of the Pharmaceutical Teaching Section and Drug Delivery Research Group of the Pharmaceutical Science Division, Kings College London, UK 12.50 - Discussion 13.00 - Lunch 14.00 u What do Inhaled Nanomedicines Offer? Professor Sally Ann Cyran, RCSI School of Pharmacy, Royal College of Surgeons, Ireland 14.40 - Electrostatic Properties of Particles for Inhalation Martin Rowland, Formulation and Process Design Scientist, Pfizer TECHNOLOGY 15.20 - Device Comparison Based on In Vitro Models Anna-Maria Ciciliani, Johannes Gutenberg-University Mainz, Germany, Department of Biopharmaceutics and Pharmaceutical Technology on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Development, Germany 16.00 - Discussion 16.15 - End of Conference and Tea For more information visit http://www.researchandmarkets.com/research/btpdfh/inhaled_drug
|